Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Q-linea AB ( (SE:QLINEA) ) has issued an update.
Q-linea AB announced a strategic update, emphasizing its goal to contract 30-40 ASTar units by 2025, with expectations to exceed 200 units by 2027. Despite a setback in the ESTAR tender in Italy, the company is expanding its market presence across Europe and the US, with significant cost reductions achieved through in-house production and a SEK 322 million rights issue to support its path to breakeven by 2027.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea is a company specializing in rapid antimicrobial susceptibility testing (AST) systems, particularly the ASTar® system, which aids hospitals in quickly identifying optimal treatments for bloodstream infections and sepsis. The company is headquartered in Uppsala, Sweden, with regional offices in Italy and the USA, and it holds CE-IVD and FDA 510(k) clearances for its products.
Average Trading Volume: 18,969
Technical Sentiment Signal: Sell
Current Market Cap: SEK235.2M
For an in-depth examination of QLINEA stock, go to TipRanks’ Overview page.